| Status | Study |
| RECRUITING |
Study Name: Venetoclax Combined With Azactidine in the Treatment of ALAL Condition: Date: 2023-06-04 Interventions: Venetoclax orally once daily (100 mg d1, 200 mg d2, 400 mg d3-28); |
| Recruiting |
Study Name: Decitabine, Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Condition: de Novo Myelodysplastic Syndrome Mixed Phenotype Acute Leukemia Date: 2016-09-29 Interventions: Drug: Cladribine Given IV |
| Recruiting |
Study Name: Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia Condition: B Acute Lymphoblastic Leukemia B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR Date: 2016-08-23 Interventions: Biological: Blinatumomab Given |
| Recruiting |
Study Name: Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement Condition: Acute Leukemia of Ambiguous Lineage Childhood B Acute Lymphobla Date: 2016-07-07 Interventions: Drug: Azacitidine Given IV |
| Recruiting |
Study Name: GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia Condition: Leukemia, Acute Lymphoblastic Acute Myeloid Leukemia Date: 2016-06-09 Interventions: Procedure: Allogeneic stem cell transplantation |
| Recruiting |
Study Name: HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide Condition: Myelodysplastic Syndrome (MDS) Chronic Lymphocytic Leukemia (CLL) Date: 2016-05-31 Interventions: Drug: Fludarabine |
| Not yet recruiting |
Study Name: Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies Condition: Hematologic Malignancy Date: 2016-03-16 Interventions: Drug: Fludarabine |
| Recruiting |
Study Name: Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib Tosylate in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Condition: Acute Biphenotypic Leukemia Acute Myeloid Leukemia Date: 2016-03-14 Interventions: Drug: Cladribine Given IV |
| Not yet recruiting |
Study Name: Standard Maintenance POMP/D Plus Ixazomib Maintenance Therapy in Adult Patients With Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma or Mixed Phenotype Acute Leukemia in Complete Remission (CR) Condition: Acute Lymphoblastic Leukemia in Complete Remission Lymphoblastic Lymphoma in Complete Remiss Date: 2015-09-30 Interventions: Drug: Ixazomib Patients who have been on stable doses of 6 - MP, vincristine, and methotrexate for a min |
| Recruiting |
Study Name: High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia Condition: Acute Leukemia of Ambiguous Lineage Recurrent Adult Acute Lymph Date: 2015-08-25 Interventions: Other: Chemosensitivity Assay |